Search

Protagonist Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

128.69 -5.64

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

127.02

Max

130.13

Pagrindiniai rodikliai

By Trading Economics

Pajamos

159M

163M

Pardavimai

157M

213M

P/E

Sektoriaus vid.

140.34

48.735

Pelnas, tenkantis vienai akcijai

2.29

Pelno marža

76.285

Darbuotojai

141

EBITDA

163M

166M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+27.55% upside

Dividendai

By Acuity

Kitas uždarbis

2026-11-04

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

846M

9.4B

Ankstesnė atidarymo kaina

134.33

Ankstesnė uždarymo kaina

128.69

Protagonist Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-10-16 20:02; UTC

Social Media

Protagonist Therapeutics Inc shares are sharply lower, diverging from a recent trend of higher daily closes, with unusually high market volume today.

2026-10-15 19:46; UTC

Social Media
Correlated Moves

UBS has initiated a Buy rating on Protagonist Therapeutics Inc with a price target of $184, highlighting the commercial potential of PN-881.

2026-10-14 20:07; UTC

Social Media

PTGX declines after Leerink initiates coverage with outperform rating.

2026-10-13 20:02; UTC

Protagonist Therapeutics Inc shares fell sharply, diverging from recent upward momentum, with unusually high trading volume observed today.

2026-10-12 20:06; UTC

News
Social Media

Protagonist Therapeutics receives a Buy rating from UBS with a $184 price target, while Leerink Partners sets an Outperform rating with a $190 target.

2026-10-09 22:21; UTC

Protagonist Therapeutics Inc shares traded modestly lower during after-market hours on Friday after peaking shortly after the regular session ended.

2026-10-08 20:07; UTC

Protagonist Therapeutics Inc shares fell amid a broadly lower market, trading near the lower end of its one-month range and below its 20-day moving average.

2026-10-07 20:01; UTC

Social Media

Protagonist Therapeutics Inc is trading higher, influenced by gains in the Biotechnology sector, despite pulling back from earlier session highs and high market volume.

2026-10-06 20:07; UTC

Protagonist Therapeutics Inc shares fell sharply, remaining near the lower end of their one-month range and below the 20-day moving average.

2026-10-01 20:07; UTC

Protagonist Therapeutics Inc shares fell as the broader market continued its decline, marking four consecutive days of lower closes and remaining below the 20-day moving average.

2026-09-30 20:07; UTC

Protagonist Therapeutics Inc shares fell sharply after peaking earlier in the day, finishing below its 20-day moving average and near the lower end of its one-month range.

2026-09-29 19:15; UTC

Social Media

Protagonist Therapeutics Inc shares fell, now near the low end of their one-month range, despite a user reporting a price target in the low $130s.

2026-09-25 19:51; UTC

Protagonist Therapeutics Inc shares are advancing significantly, showing strong upward momentum with notable trading activity since Thursday's close.

2026-09-24 19:46; UTC

Protagonist Therapeutics Inc shares fell sharply, reaching a low before noon and trading significantly below its 20-day moving average amid ongoing biotechnology sector weakness.

2026-09-23 20:02; UTC

Protagonist Therapeutics Inc shares fell sharply, continuing a decline since Tuesday, with trading volume unusually high and prices near the lower end of their one-month range.

2026-09-18 20:06; UTC

Protagonist Therapeutics Inc shares fell sharply, remaining below their 20-day moving average and near the lower end of their one-month range.

2026-09-17 19:46; UTC

Protagonist Therapeutics Inc shares are trading roughly flat, currently below their opening level and the 20-day moving average after three consecutive lower closes.

2026-09-16 19:13; UTC

Protagonist Therapeutics Inc shares fell sharply amid a broader market decline, influenced by mixed economic data and cautious investor sentiment ahead of jobless claims.

2026-09-15 20:07; UTC

Protagonist Therapeutics shares are lower amid broader market concerns, following a significant drop in the NY Empire State Manufacturing Index for September.

2026-09-11 20:08; UTC

News

Protagonist Therapeutics shares are higher as CEO Dinesh V. Patel exercises options and sells over 70,000 shares, boosting investor sentiment.

2026-09-09 20:07; UTC

News
Social Media

Protagonist Therapeutics announced a $300 million share repurchase program, but shares are trading lower during Wednesday's session after pulling back from an earlier high.

2026-09-02 20:08; UTC

Social Media

Protagonist Therapeutics shares are lower despite Barclays setting a $180 price target following the approval of Mimrylo for polycythemia vera treatment.

2026-09-01 19:36; UTC

News
Social Media

Protagonist Therapeutics shares are lower today, despite analysts raising price targets following the approval of Mimrylo. Barclays set a target of $180.

2026-08-28 20:02; UTC

Protagonist Therapeutics Inc is declining during Friday's session, reversing earlier gains amid rising U.S. Treasury yields and broader market dynamics.

2026-08-27 20:07; UTC

Protagonist Therapeutics Inc shares are lower during Thursday's session, continuing a decline since Wednesday amid broader market conditions and economic resilience signals.

2026-08-26 20:08; UTC

Protagonist Therapeutics Inc shares are trading higher today. No specific news was identified to explain the movement amid mixed broader market conditions.

2026-08-25 23:36; UTC

Protagonist Therapeutics Inc. sees modest gains in after-market trading amid a broader market backdrop of declining crude oil prices and easing geopolitical tensions.

2026-08-24 20:06; UTC

Protagonist Therapeutics shares are higher today, recovering from an earlier dip. The broader market also shows slight gains since Friday's close.

2026-08-21 20:06; UTC

Protagonist Therapeutics Inc is rising during Friday's session, showing steady gains since Thursday amid a broader market boost from Bitcoin's surge.

2026-08-20 19:31; UTC

Correlated Moves

Protagonist Therapeutics Inc shares are lower today amid a decline in the Biotechnology sector, with unusually high trading volume noted during the session.

Akcijų palyginimas

Kainos pokytis

Protagonist Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

27.55% į viršų

12 mėnesių prognozė

Vidutinis 174.167 USD  27.55%

Aukščiausias 190 USD

Žemiausias 149 USD

Remiantis 13 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Protagonist Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

13 ratings

13

Pirkti

0

Laikyti

0

Parduoti

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Protagonist Therapeutics Inc

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
help-icon Live chat